Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 4 | 13 | — | — | 17 |
Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 2 | 4 | — | — | 6 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Insulin resistance | D007333 | HP_0000855 | — | — | 1 | — | — | — | 1 |
Drug common name | Tesaglitazar |
INN | tesaglitazar |
Description | Tesaglitazar (also known as AZ 242) is a dual peroxisome proliferator-activated receptor agonist with affinity to PPARα and PPARγ, proposed for the management of type 2 diabetes.
|
Classification | Small molecule |
Drug class | peroxisome proliferator activiating receptor (PPAR) agonists (not thiazolidene derivatives) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(=O)O |
PDB | — |
CAS-ID | 251565-85-2 |
RxCUI | — |
ChEMBL ID | CHEMBL282686 |
ChEBI ID | — |
PubChem CID | 208901 |
DrugBank | — |
UNII ID | 6734037O3L (ChemIDplus, GSRS) |